Champions Oncology, Inc.
CSBR
$5.96
$0.111.88%
NASDAQ
| 01/31/2026 | 10/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 10.14% | 7.43% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.14% | 7.43% | |||
| Cost of Revenue | 21.65% | -9.17% | |||
| Gross Profit | -0.62% | 29.55% | |||
| SG&A Expenses | 13.46% | 12.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.77% | 2.40% | |||
| Operating Income | -201.08% | 136.49% | |||
| Income Before Tax | -192.94% | 156.42% | |||
| Income Tax Expenses | 133.33% | 28.57% | |||
| Earnings from Continuing Operations | -217.72% | 150.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | 3.33% | |||
| Net Income | -204.10% | 161.47% | |||
| EBIT | -201.08% | 136.49% | |||
| EBITDA | -71.59% | 463.76% | |||
| EPS Basic | -203.61% | 161.39% | |||
| Normalized Basic EPS | -148.55% | 179.31% | |||
| EPS Diluted | -203.61% | 161.39% | |||
| Normalized Diluted EPS | -150.76% | 175.86% | |||
| Average Basic Shares Outstanding | 0.69% | 0.03% | |||
| Average Diluted Shares Outstanding | -3.95% | 4.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||